PharmaFocus Today – Page 29 – media

Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the accumulation of fat in liver cells, which has severe liver consequences and is also associated with a high mortality rate from cardiovascular disease. Now, a University of Barcelona study published in the journal Pharmacological Research shows that pemafibrate and telmisartan, two drugs already approved for other conditions, effectively reduce fat accumulation in laboratory animal models of metabolic liver disease. Furthermore, the study suggests that this combination of drugs may help to reduce both liver involvement and associated cardiovascular complications. These results open the door to the development of safer and more effective treatments for this disease, for which current therapeutic options are very limited. The study has been carried out by a team led by Marta Alegret, professor at the ...
- Source: drugdu
- 166
- October 7, 2025
Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks

While the virus is common in tropical and subtropical regions, including Asia, Africa and South America, public health officials have been tracking reported infections in Europe and, in September, a confirmed case in Long Island, New York. Outbreaks of chikungunya have prompted the Centers for Disease Control to issue health notices to travelers bound for Bangladesh; Cuba; Guangdong Province, China; Kenya; Madagascar; Somalia; and Sri Lanka. In Guangdong Province, an”unprecedented”outbreak recently prompted government officials in China to mandate quarantines for anyone suspected of being infected by the virus, spraying individuals with mosquito repellent and spraying impacted buildings and other areas with insecticide. In a new study, published in Science Advances, researchers at the University of Notre Dame analyzed more than 80 outbreaks of chikungunya virus to improve prediction of future outbreaks and inform vaccine trial development. “Chikungunya outbreaks are unpredictable in both size and severity,”said Alex ...
- Source: drugdu
- 146
- October 7, 2025
UK health agency urges people to get vaccinated against respiratory viruses before winter

The UK Health and Safety Agency (UKHSA) announced on the 26th that as winter approaches, influenzaThe number of cases of COVID-19, COVID-19 and respiratory syncytial virus (RSV) is on the rise, and the public is urged to make appointments for relevant vaccines as soon as possible. 　　The latest UK national influenza and COVID-19 surveillance report shows that related cases have been steadily increasing over the past few weeks. The COVID-19 positive rate has risen from 7.6% to 8.4% in one week, and the number of COVID-19 hospitalizations per 100,000 people has also increased from 2 to 2.73. UKHSA emphasizes that before the peak season of respiratory diseases arrives, people should receive timely medical treatment from the UK National Health Service.The free vaccinations are provided by the National Health Service (NHS). Pregnant women and millions of children are already eligible for the vaccine, and most eligible groups can make an appointment from October 1. This ...
- Source: https://finance.eastmoney.com/a/202509263525102518.html
- 145
- October 6, 2025
Beike Bio responded to the inquiry letter regarding its semi-annual report and detailed the reasons for the decline in herpes zoster vaccine sales.

Beike BioA response was made to the regulatory inquiry letter regarding information disclosure in the 2025 semi-annual report, mentioning the reasons for the decline in sales of shingles vaccine. 　　In the first half of 2025, the company’s operating income was 285 million yuan, a year-on-year decrease of 53.93%; the net profit was -73.5734 million yuan, turning from profit to loss year-on-year. The company disclosed that the decline in performance was mainly due to the decline in sales of shingles vaccine. 　　The announcement showed that during the reporting period, the company’s sales volume of shingles vaccine was -17,300 doses, with sales revenue of -65.2266 million yuan. 　　Beike Bio believes that factors such as product price structure, vaccination demand, low disease awareness, insufficient consumption willingness of the applicable group, and vaccine hesitation affect the product revenue. 　　The company stated in its response that during the reporting period, sales of herpes zoster vaccines decreased ...
- Source: https://finance.eastmoney.com/a/202509303526642756.html
- 150
- October 6, 2025
Dongcheng Pharmaceutical’s subsidiary’s new prostate cancer drug approved for clinical trials

Dongcheng Pharmaceutical recently announced that its controlling subsidiary, Lannacheng, has received approval from the National Medical Products Administration (NMPA) for the clinical trial of 225Ac-LNC1011 injection, authorizing it to conduct clinical trials for prostate cancer. This drug, an alpha-particle radioactive in vivo therapeutic targeting prostate-specific membrane antigen (PSMA), is intended for the treatment of patients with advanced prostate cancer who are PSMA-positive. Currently, no similar product is marketed outside of China , and no sales data is available. The project has invested approximately 14.53 million yuan in R&D. In completed animal and human trials, 225Ac-LNC1011 injection has demonstrated therapeutic potential for prostate cancer. However, the drug development cycle, clinical trial approval, and production are long and involve many steps. Investors need to be aware of the risk of drug development failure.
- Source: https://www.stcn.com/article/detail/3353547.html
- 150
- October 5, 2025
Rectal bleeding increases the odds of colorectal cancer diagnosis by 8.5 times

Adults under 50 undergoing colonoscopy were found to have a dramatically higher risk of having colorectal cancer when the procedure was done for rectal bleeding. Researchers found that rectal bleeding increased the odds of a colorectal cancer diagnosis by 8.5 times, underscoring the need to take the symptom seriously even in the absence of a family history in a population who may not otherwise meet screening age criteria. The research will be presented at the American College of Surgeons (ACS) Clinical Congress 2025 in Chicago, October 4-7. The retrospective study analyzed 443 patients under 50 who underwent a colonoscopy at the University of Louisville Health System between 2021 and 2023. Of them, 195 (44%) were diagnosed with early-onset colorectal cancer, while 248 (56%) had normal results. “Many of the early-onset colorectal cancers that I see have no family history. This research lends support to the question of ...
- Source: drugdu
- 140
- October 5, 2025
FDA Announces New Domestic Generic Drug Fast-Track Review Program

FDA announced a new pilot program designed to provide faster reviews for domestically tested and manufactured generic drugs. The program is part of a larger initiative to promote and reward domestic investments by pharmaceutical companies. The abbreviated new drug applications (ANDAs) are meant to strengthen the domestic pharmaceutical supply chain while also helping to get less expensive drugs to market sooner. In a press release, director of FDA’s Center for Drug Evaluation and Research Dr. George Tidmarsh, MD, PhD, said, “Ensuring that Americans have access to high-quality, safe and effective generic medicines is critical to public health. Overreliance on foreign drug manufacturing and testing creates risks both to national security and patient access, and undermines investments in U.S. research, manufacturing and production. It also slows down reviews and costs taxpayers more money, as these foreign research and testing sites must be inspected by FDA, and foreign inspections take ...
- Source: drugdu
- 159
- October 5, 2025
World’s first vaccine trial against elephant endotheliotropic herpesvirus proves safe and effective

The world’s first vaccine trial against elephant endotheliotropic herpesvirus (EEHV) – a leading cause of death in young Asian elephants – is safe and triggers a strong virus-fighting immune response, according to an international team led by the University of Surrey, in collaboration with Chester Zoo and the Animal and Plant Health Agency. Published in Nature Communications, the proof‑of‑concept study involved adult elephants at Chester Zoo. No side effects were seen, and the vaccine successfully activated a key part of the immune system that helps fight viruses. The results suggest the vaccine could prevent deadly EEHV disease in calves – the group most at risk – and support conservation breeding programmes worldwide. Professor Falko Steinbach, senior author of the study and Professor of Veterinary Immunology at the University of Surrey, said: “This is a landmark moment in our work to develop safe and efficacious vaccines. For the first time, we have ...
- Source: Medical News
- 154
- October 4, 2025
FDA Signs Off on New Version of Abortion Pill Mifepristone

A new low-cost version of the abortion pill mifepristone just received federal approval and it’s already stirring political controversy. The U.S. Food and Drug Administration (FDA) recently granted approval to Evita Solutions for its generic version of mifepristone, a medication used to end early pregnancies up to 10 weeks. The original version of mifepristone has been available in the U.S. for 25 years and is commonly prescribed alongside another medication, misoprostol, to complete a medication abortion. Evita “believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care,” the company said. While the approval process for generic drugs is usually routine, this decision quickly caused backlash from anti-abortion groups, The Associated Press reported. Students for Life Action called the approval “a stain on the Trump presidency and another sign that the deep state at the FDA must go.” Meanwhile, Republican ...
- Source: Healthday
- 167
- October 4, 2025
Kangtai Biological and AstraZeneca terminate cooperation on adenovirus vector COVID-19 vaccine

On September 30, Kangtai Biological(300601) issued an announcement that the company signed a license termination agreement with AstraZeneca UK Limited (AstraZeneca) to terminate the cooperation in the research and development, production and commercialization of ChAdOx1 adenovirus vector new crown vaccine. The termination of the cooperation on the licensed product and the signing of the termination agreement are prudent decisions made by the company after comprehensive assessment of factors such as the prevalent strains of the new coronavirus vaccine and the significant changes in the market environment, as well as its own resource allocation. The company mentioned that in the future it will concentrate its superior resources to focus on the research and development and industrialization of multi-component and multivalent vaccines, adult vaccines, innovative vaccines, and therapeutic vaccines, continue to deepen its roots in the vaccine field, and enhance its core competitiveness. By mid-2025, CanSino Biologics achieved revenue of 1.392 billion yuan and net ...
- Source: drugdu
- 149
- October 3, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.